Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
3billion | RCV002284021 | SCV002573343 | likely pathogenic | Polycystic kidney disease 2 | 2022-09-01 | criteria provided, single submitter | clinical testing | The variant is not observed in the gnomAD v2.1.1 dataset. Frameshift variant is predicted to result in a loss or disruption of normal protein function through nonsense-mediated decay (NMD) or protein truncation. Multiple pathogenic variants are reported downstream of the variant. Therefore, this variant is classified as Likely pathogenic according to the recommendation of ACMG/AMP guideline. |
Fulgent Genetics, |
RCV002284021 | SCV005667924 | pathogenic | Polycystic kidney disease 2 | 2024-02-15 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV005096040 | SCV005745635 | pathogenic | Autosomal dominant polycystic kidney disease | 2024-03-16 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Leu231Serfs*2) in the PKD2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in PKD2 are known to be pathogenic (PMID: 17582161, 22863349). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with PKD2-related conditions. ClinVar contains an entry for this variant (Variation ID: 1705707). For these reasons, this variant has been classified as Pathogenic. |